321 related articles for article (PubMed ID: 11583969)
21. α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.
Ikeda H; Sato Y; Yoneda N; Harada K; Sasaki M; Kitamura S; Sudo Y; Ooi A; Nakanuma Y
Hum Pathol; 2012 Nov; 43(11):1955-63. PubMed ID: 22516245
[TBL] [Abstract][Full Text] [Related]
22. Cytokeratin patterns of liver carcinomas induced by diethylnitrosamine in monkeys.
Lapis K; Sarosi I; Bocsi J; Thorgeirsson UP
Lab Invest; 1995 Jun; 72(6):748-59. PubMed ID: 7540236
[TBL] [Abstract][Full Text] [Related]
23. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma.
Ushiku T; Shinozaki A; Shibahara J; Iwasaki Y; Tateishi Y; Funata N; Fukayama M
Am J Surg Pathol; 2010 Apr; 34(4):533-40. PubMed ID: 20182341
[TBL] [Abstract][Full Text] [Related]
24. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms.
Mounajjed T; Zhang L; Wu TT
Hum Pathol; 2013 Apr; 44(4):542-50. PubMed ID: 23079207
[TBL] [Abstract][Full Text] [Related]
25. An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19.
Tsuji M; Kashihara T; Terada N; Mori H
Pathol Int; 1999 Apr; 49(4):310-7. PubMed ID: 10365850
[TBL] [Abstract][Full Text] [Related]
26. Expression of alpha-fetoprotein and albumin genes in human hepatocellular carcinomas: limitations in the application of the genes for targeting human hepatocellular carcinoma in gene therapy.
Ohguchi S; Nakatsukasa H; Higashi T; Ashida K; Nouso K; Ishizaki M; Hino N; Kobayashi Y; Uematsu S; Tsuji T
Hepatology; 1998 Feb; 27(2):599-607. PubMed ID: 9462663
[TBL] [Abstract][Full Text] [Related]
27. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma.
Nishino R; Honda M; Yamashita T; Takatori H; Minato H; Zen Y; Sasaki M; Takamura H; Horimoto K; Ohta T; Nakanuma Y; Kaneko S
J Hepatol; 2008 Aug; 49(2):207-16. PubMed ID: 18490072
[TBL] [Abstract][Full Text] [Related]
28. PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma.
He F; Yan Q; Fan L; Liu Y; Cui J; Wang J; Wang L; Wang Y; Wang Z; Guo Y; Huang G
Hum Pathol; 2010 Mar; 41(3):415-24. PubMed ID: 19954816
[TBL] [Abstract][Full Text] [Related]
29. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.
Zimmerman RL; Fogt F; Burke M; Murakata LA
Oncol Rep; 2002; 9(4):689-92. PubMed ID: 12066193
[TBL] [Abstract][Full Text] [Related]
30. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
Shirakawa H; Kuronuma T; Nishimura Y; Hasebe T; Nakano M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Int J Oncol; 2009 Mar; 34(3):649-56. PubMed ID: 19212669
[TBL] [Abstract][Full Text] [Related]
31. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors.
Terada T; Okada Y; Nakanuma Y
Hepatology; 1996 Jun; 23(6):1341-4. PubMed ID: 8675149
[TBL] [Abstract][Full Text] [Related]
32. The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma.
Aishima S; Asayama Y; Taguchi K; Sugimachi K; Shirabe K; Shimada M; Sugimachi K; Tsuneyoshi M
Mod Pathol; 2002 Nov; 15(11):1181-90. PubMed ID: 12429797
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration cytology.
Saad RS; Luckasevic TM; Noga CM; Johnson DR; Silverman JF; Liu YL
Diagn Cytopathol; 2004 Jan; 30(1):1-6. PubMed ID: 14696137
[TBL] [Abstract][Full Text] [Related]
34. A mixed hepatocellular carcinoma and cholangiocarcinoma: dual expression of biliary-type cytokeratin and hepatocyte specific marker.
Tanaka S; Hirohashi K; Uenishi T; Yamamoto T; Hamba H; Kubo S; Tanaka H; Shuto T; Ogawa M; Kinoshita H
Hepatogastroenterology; 2004; 51(57):839-41. PubMed ID: 15143930
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic utility of CD10 in benign and malignant extrahepatic bile duct lesions.
Tretiakova M; Antic T; Westerhoff M; Mueller J; Himmelfarb EA; Wang HL; Xiao SY
Am J Surg Pathol; 2012 Jan; 36(1):101-8. PubMed ID: 21989348
[TBL] [Abstract][Full Text] [Related]
36. Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas.
Riener MO; Fritzsche FR; Soll C; Pestalozzi BC; Probst-Hensch N; Clavien PA; Jochum W; Soltermann A; Moch H; Kristiansen G
Histopathology; 2010 Apr; 56(5):600-6. PubMed ID: 20459570
[TBL] [Abstract][Full Text] [Related]
37. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein.
Chu PG; Ishizawa S; Wu E; Weiss LM
Am J Surg Pathol; 2002 Aug; 26(8):978-88. PubMed ID: 12170084
[TBL] [Abstract][Full Text] [Related]
38. Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma.
Kawahara N; Ono M; Taguchi K; Okamoto M; Shimada M; Takenaka K; Hayashi K; Mosher DF; Sugimachi K; Tsuneyoshi M; Kuwano M
Hepatology; 1998 Dec; 28(6):1512-7. PubMed ID: 9828214
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin.
Komuta M; Spee B; Vander Borght S; De Vos R; Verslype C; Aerts R; Yano H; Suzuki T; Matsuda M; Fujii H; Desmet VJ; Kojiro M; Roskams T
Hepatology; 2008 May; 47(5):1544-56. PubMed ID: 18393293
[TBL] [Abstract][Full Text] [Related]
40. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: 'bile ductular carcinoma'.
Kozaka K; Sasaki M; Fujii T; Harada K; Zen Y; Sato Y; Sawada S; Minato H; Matsui O; Nakanuma Y
Histopathology; 2007 Sep; 51(3):390-400. PubMed ID: 17553067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
